Landscape Capital Management L.L.C. Buys New Stake in Elanco Animal Health Incorporated $ELAN

Landscape Capital Management L.L.C. purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 114,471 shares of the company’s stock, valued at approximately $2,817,000.

A number of other institutional investors also recently bought and sold shares of ELAN. NewEdge Advisors LLC increased its holdings in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Elanco Animal Health during the 2nd quarter worth about $38,000. Root Financial Partners LLC lifted its stake in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. purchased a new stake in Elanco Animal Health during the fourth quarter worth approximately $41,000. Finally, Torren Management LLC purchased a new position in Elanco Animal Health in the fourth quarter valued at approximately $46,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Michael J. Harrington bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the purchase, the director owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert M. Vanhimbergen purchased 4,200 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the acquisition, the chief financial officer owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ELAN shares. UBS Group boosted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Citigroup boosted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $24.05 on Friday. The firm’s fifty day simple moving average is $24.56 and its 200-day simple moving average is $24.01. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The stock has a market capitalization of $12.02 billion, a price-to-earnings ratio of -58.66, a PEG ratio of 1.41 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the prior year, the business earned $0.26 EPS. Elanco Animal Health’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.